BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 25583594)

  • 1. [Fabry disease from the neurologist's point of view: is it a rare cause of strokes?].
    Marti-Martinez S; Climent V; Pampliega-Perez A; Martin-Estefania C; Leiva-Santana C
    Rev Neurol; 2015 Jan; 60(2):93-5. PubMed ID: 25583594
    [No Abstract]   [Full Text] [Related]  

  • 2. Case report of concurrent Fabry disease and amyotrophic lateral sclerosis supports a common pathway of pathogenesis.
    Beer AM; Cooper-Knock J; Fletcher S; Brown-Wright SH; Nandakumar TP; Shaw PJ
    Amyotroph Lateral Scler Frontotemporal Degener; 2016; 17(7-8):614-616. PubMed ID: 27094629
    [No Abstract]   [Full Text] [Related]  

  • 3. [Diagnosis of Fabry disease: usefulness of the clinical investigation].
    Demontis R
    Rev Med Interne; 2010 Dec; 31 Suppl 2():S229-32. PubMed ID: 21211670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nephropathy in Fabry disease: the importance of early diagnosis and testing in high-risk populations.
    Oqvist B; Brenner BM; Oliveira JP; Ortiz A; Schaefer R; Svarstad E; Wanner C; Zhang K; Warnock DG
    Nephrol Dial Transplant; 2009 Jun; 24(6):1736-43. PubMed ID: 19293136
    [No Abstract]   [Full Text] [Related]  

  • 5. Stroke and Chronic Kidney Disease in Fabry Disease.
    Tapia D; Kimonis V
    J Stroke Cerebrovasc Dis; 2021 Sep; 30(9):105423. PubMed ID: 33160817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fabry disease. Classic hemizygote and residual alpha-galactosidase A activity.
    Pravata G; Noto G; Arico M
    Int J Dermatol; 1991 May; 30(5):367-9. PubMed ID: 1648549
    [No Abstract]   [Full Text] [Related]  

  • 7. Proposed high-risk screening protocol for Fabry disease in patients with renal and vascular disease.
    Auray-Blais C; Millington DS; Young SP; Clarke JT; Schiffmann R
    J Inherit Metab Dis; 2009 Apr; 32(2):303-8. PubMed ID: 19169844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paradoxical Response to Enzyme Replacement Therapy of Fabry Disease Cardiomyopathy.
    Frustaci A; Russo MA; Chimenti C
    Circ Cardiovasc Imaging; 2016 Aug; 9(8):. PubMed ID: 27486136
    [No Abstract]   [Full Text] [Related]  

  • 9. Young woman with recurrent ischemic strokes diagnosed as Fabry disease: lessons learned from a case report.
    Zenone T; Chan V
    Clin Neurol Neurosurg; 2011 Sep; 113(7):586-8. PubMed ID: 21420783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment strategy for Fabry's disease following a stroke].
    Torralba-Cabeza MA; Olivera-González S; Josa-Laorden C; Sierra JL; Pérez-Calvo JI
    Rev Neurol; 2015 Jun; 60(12):574. PubMed ID: 26062831
    [No Abstract]   [Full Text] [Related]  

  • 11. [Enzyme replacement therapy in Fabry's disease].
    Alvarez L; del Pozo C; Trigueros M; Sánchez L; Albero MD; López-Menchero R; Ortega E
    Nefrologia; 2005; 25(3):322-7. PubMed ID: 16053014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amelioration of white-matter lesions in a patient with Fabry disease.
    Yamadera M; Yokoe M; Beck G; Mihara M; Oe H; Yamamoto Y; Sakoda S
    J Neurol Sci; 2009 Apr; 279(1-2):118-20. PubMed ID: 19185318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment strategy for Fabry's disease following a stroke. Reply].
    Martí-Martínez S; Climent V; Pampliega-Pérez A; Martín-Estefanía C; Leiva-Santana C
    Rev Neurol; 2015 Jun; 60(12):574-6. PubMed ID: 26062832
    [No Abstract]   [Full Text] [Related]  

  • 14. [Fabry disease].
    Jakubowska E; Ryba M; Hruby Z
    Przegl Lek; 2006; 63(4):218-9. PubMed ID: 17080745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of antibody formation on reduction of globotriaosylceramide (GL-3) in urine from Fabry patients during agalsidase beta therapy.
    Ohashi T; Sakuma M; Kitagawa T; Suzuki K; Ishige N; Eto Y
    Mol Genet Metab; 2007 Nov; 92(3):271-3. PubMed ID: 17689998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and genetic analysis of Fabry disease: report of six cases including three heterozygous females.
    Nagasaki A; Nishie W; Sato K; Oba I; Noguchi E; Akitsu H; Sawamura D; Shimizu H
    J Dermatol Sci; 2008 Oct; 52(1):61-4. PubMed ID: 18555667
    [No Abstract]   [Full Text] [Related]  

  • 17. [Management of Fabry disease].
    Constantin T; Székely A; Ponyi A; Gulácsy V; Ambrus C; Kádár K; Vastagh I; Dajnoki A; Tóth B; Bokrétás G; Müller V; Katona M; Medvecz M; Fiedler O; Széchey R; Varga E; Rudas G; Kertész A; Molnár S; Kárpáti S; Nagy V; Magyar P; Mahdi M; Rákóczi E; Németh K; Bereczki D; Garami M; Erdos M; Maródi L; Fekete G
    Orv Hetil; 2010 Aug; 151(31):1243-51. PubMed ID: 20656661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fabry disease previously diagnosed as Henoch-Schonlein purpura.
    Kim JH; Han DH; Park MY; Choi SJ; Kim JK; Hwang SD; Jin SY
    Korean J Intern Med; 2015 Nov; 30(6):925-7. PubMed ID: 26552470
    [No Abstract]   [Full Text] [Related]  

  • 19. [Contribution of the measurement of globotriaosylceramide in urine to the diagnosis and follow-up of Fabry disease].
    Piraud M; Maire I; Froissart R
    Rev Med Interne; 2010 Dec; 31 Suppl 2():S270-4. PubMed ID: 21211678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enzyme replacement therapy in two Japanese siblings with Fabry disease, and its effectiveness on angiokeratoma and neuropathic pain.
    Furujo M; Kubo T; Kobayashi M; Ohashi T
    Mol Genet Metab; 2013 Nov; 110(3):405-10. PubMed ID: 23906479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.